LENZING AG(FRA:LEN) stock Fundamental Analysis

Fundamental Rating

Overall LEN gets a fundamental rating of 2 out of 10. We evaluated LEN against 61 industry peers in the Chemicals industry. LEN has a bad profitability rating. Also its financial health evaluation is rather negative. LEN is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

LEN had negative earnings in the past year.

In the past year LEN had a positive cash flow from operations.

The reported net income has been mixed in the past 5 years: LEN reported negative net income in multiple years.

Of the past 5 years LEN 4 years had a positive operating cash flow.

1.2 Ratios

LEN's Return On Assets of -12.37% is on the low side compared to the rest of the industry. LEN is outperformed by 74.60% of its industry peers.

LEN has a worse Return On Equity (-51.83%) than 77.78% of its industry peers.

		Industry Rank	Sector Rank
ROA	-12.37%
ROE	-51.83%
ROIC	N/A

ROA(3y)-3.9%

ROA(5y)-1.52%

ROE(3y)-14.47%

ROE(5y)-6.99%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

In the last couple of years the Operating Margin of LEN has declined.

Looking at the Gross Margin, with a value of 1.66%, LEN is doing worse than 82.54% of the companies in the same industry.

LEN's Gross Margin has declined in the last couple of years.

The Profit Margin and Operating Margin are not available for LEN so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	1.66%

OM growth 3Y-1.52%

OM growth 5Y-21.86%

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-28.96%

GM growth 5Y-17.99%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

LEN does not have a ROIC to compare to the WACC, probably because it is not profitable.

LEN has more shares outstanding than it did 1 year ago.

LEN has more shares outstanding than it did 5 years ago.

Compared to 1 year ago, LEN has a worse debt to assets ratio.

2.2 Solvency

LEN has an Altman-Z score of 0.74. This is a bad value and indicates that LEN is not financially healthy and even has some risk of bankruptcy.

LEN has a worse Altman-Z score (0.74) than 73.02% of its industry peers.

LEN has a debt to FCF ratio of 10.49. This is a negative value and a sign of low solvency as LEN would need 10.49 years to pay back of all of its debts.

LEN has a Debt to FCF ratio (10.49) which is comparable to the rest of the industry.

LEN has a Debt/Equity ratio of 1.45. This is a high value indicating a heavy dependency on external financing.

The Debt to Equity ratio of LEN (1.45) is worse than 82.54% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	1.45
Debt/FCF	10.49
Altman-Z	0.74

ROIC/WACCN/A

WACC6.14%

2.3 Liquidity

LEN has a Current Ratio of 1.48. This is a normal value and indicates that LEN is financially healthy and should not expect problems in meeting its short term obligations.

With a Current ratio value of 1.48, LEN is not doing good in the industry: 61.90% of the companies in the same industry are doing better.

A Quick Ratio of 1.02 indicates that LEN should not have too much problems paying its short term obligations.

LEN has a Quick ratio (1.02) which is in line with its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.48
Quick Ratio	1.02

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

LEN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -88.63%.

LEN shows a small growth in Revenue. In the last year, the Revenue has grown by 6.19%.

LEN shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.99% yearly.

EPS 1Y (TTM)-88.63%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-71.13%

Revenue 1Y (TTM)6.19%

Revenue growth 3Y15.59%

Revenue growth 5Y2.99%

Sales Q2Q%5.2%

3.2 Future

Based on estimates for the next years, LEN will show a very strong growth in Earnings Per Share. The EPS will grow by 24.00% on average per year.

The Revenue is expected to grow by 3.27% on average over the next years.

EPS Next Y82.82%

EPS Next 2Y38.9%

EPS Next 3Y33%

EPS Next 5Y24%

Revenue Next Year6.85%

Revenue Next 2Y5.04%

Revenue Next 3Y5.72%

Revenue Next 5Y3.27%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LEN. In the last year negative earnings were reported.

Also next year LEN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, LEN is valued a bit cheaper than 74.60% of the companies in the same industry.

Based on the Price/Free Cash Flow ratio, LEN is valued cheaply inside the industry as 95.24% of the companies are valued more expensively.

		Industry Rank	Sector Rank
P/FCF	5.06
EV/EBITDA	7.49

4.3 Compensation for Growth

A more expensive valuation may be justified as LEN's earnings are expected to grow with 33.00% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y38.9%

EPS Next 3Y33%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

LEN does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

LENZING AG

FRA:LEN (3/7/2025, 7:00:00 PM)

29.15

+0.3 (+1.04%)

Chartmill FA Rating

GICS SectorMaterials

GICS IndustryGroupMaterials

GICS IndustryChemicals

Earnings (Last)11-07 2024-11-07

Earnings (Next)03-14 2025-03-14/amc

Inst Owners19.14%

Inst Owner ChangeN/A

Ins OwnersN/A

Ins Owner ChangeN/A

Market Cap1.13B

Analysts51.67

Price Target33.57 (15.16%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly Dividend0.84

Dividend Growth(5Y)-29.99%

DP-4.59%

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)-3.49%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)60.51%

EPS NY rev (3m)63.81%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)-1.51%

Revenue NY rev (3m)-2.4%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	0.43
P/FCF	5.06
P/OCF	2.91
P/B	0.92
P/tB	0.92
EV/EBITDA	7.49

EPS(TTM)-16.4

EYN/A

EPS(NY)-0.4

Fwd EYN/A

FCF(TTM)5.76

FCFY19.77%

OCF(TTM)10

OCFY34.31%

SpS67.67

BVpS31.77

TBVpS31.77

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-12.37%
ROE	-51.83%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	1.66%
FCFM	8.52%

ROA(3y)-3.9%

ROA(5y)-1.52%

ROE(3y)-14.47%

ROE(5y)-6.99%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)2.31%

ROCE(5y)3.07%

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3Y-1.52%

OM growth 5Y-21.86%

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-28.96%

GM growth 5Y-17.99%

F-Score3

Asset Turnover0.51

Health

		Industry Rank	Sector Rank
Debt/Equity	1.45
Debt/FCF	10.49
Debt/EBITDA	5.08
Cap/Depr	21.05%
Cap/Sales	6.26%
Interest Coverage	N/A
Cash Conversion	110.4%
Profit Quality	N/A
Current Ratio	1.48
Quick Ratio	1.02
Altman-Z	0.74

F-Score3

WACC6.14%

ROIC/WACCN/A

Cap/Depr(3y)285.11%

Cap/Depr(5y)283.66%

Cap/Sales(3y)25.45%

Cap/Sales(5y)25.78%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-88.63%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-71.13%

EPS Next Y82.82%

EPS Next 2Y38.9%

EPS Next 3Y33%

EPS Next 5Y24%

Revenue 1Y (TTM)6.19%

Revenue growth 3Y15.59%

Revenue growth 5Y2.99%

Sales Q2Q%5.2%

Revenue Next Year6.85%

Revenue Next 2Y5.04%

Revenue Next 3Y5.72%

Revenue Next 5Y3.27%

EBIT growth 1Y-300.88%

EBIT growth 3Y13.83%

EBIT growth 5Y-19.53%

EBIT Next Year11466.8%

EBIT Next 3Y448.24%

EBIT Next 5Y267.01%

FCF growth 1Y135.66%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y219.11%

OCF growth 3Y48.51%

OCF growth 5Y-10.55%

LENZING AG (LEN.DE) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens